08/06/2026
📢 We are pleased to share our latest publication on cortical lesion evolution in relapsing-remitting multiple sclerosis patients treated with ocrelizumab.
Over a 2-year follow-up, we observed no new cortical lesion formation, supporting the potential role of ocrelizumab in limiting cortical pathology and reinforcing the value of cortical lesions as an early marker of disease severity in MS.
https://doi.org/10.1016/j.neurot.2026.e00940
